Mankind Pharma Limited has successfully acquired the remaining 10% stake in Upakarma Ayurveda Private Limited from Kaushcorp Media LLP for ₹75 Lakhs. This strategic move, completed on June 2, 2026, makes Upakarma Ayurveda a wholly-owned subsidiary (WOS) of Mankind Lifesciences Private Limited (MLS) and a step-down WOS of Mankind Pharma. The acquisition is expected to enhance operational efficiencies and streamline processes within the ayurvedic and nutraceutical segments.
Mankind Pharma Completes Upakarma Ayurveda Acquisition
Mankind Pharma Limited, through its wholly-owned subsidiary Mankind Lifesciences Private Limited (MLS), has finalized the acquisition of the remaining 10% stake in Upakarma Ayurveda Private Limited. This transaction was executed via a Share Purchase Agreement (SPA) with Kaushcorp Media LLP, for a consideration of ₹75 Lakhs, payable in two tranches. The deal was officially completed on June 2, 2026.
Strategic Implications of the Acquisition
Prior to this acquisition, MLS held a 90% stake in Upakarma Ayurveda. With the purchase of the additional 10%, Upakarma Ayurveda now becomes a wholly-owned subsidiary of MLS. Consequently, it is also recognized as a step-down wholly-owned subsidiary of Mankind Pharma Limited. This move is anticipated to foster greater operational efficiencies and streamline business processes within the company’s ayurvedic, herbal, and nutraceutical product lines.
Upakarma Ayurveda: Key Details
Upakarma Ayurveda Private Limited, incorporated on November 28, 2017, is primarily engaged in the trading and selling of ayurvedic, herbal, and nutraceutical products. The company reported a turnover of ₹18.02 Crores for the financial year 2025-26. It previously became a step-down subsidiary of Mankind Pharma on November 9, 2022. The company’s authorized share capital stands at ₹2.00 Crores, with a paid-up share capital of ₹1.80 Crores.
Financials and Deal Rationale
The consideration for acquiring the remaining 10% stake amounts to ₹75 Lakhs. The acquisition is classified as a Related Party Transaction but is conducted on an arm’s length basis, with no direct interest from the promoters or promoter group of Mankind Pharma. The primary objective behind this acquisition is to achieve enhanced operational efficiencies through a more integrated and streamlined business approach.
Turnover Snapshot of Upakarma Ayurveda
The financial performance of Upakarma Ayurveda over recent years highlights consistent activity:
- 2025-26: ₹18.02 Crores
- 2024-25: ₹13.06 Crores
- 2023-24: ₹23.04 Crores
Source: BSE
